Threats to the value of Health Technology Assessment: Qualitative evidence from Canada and Poland

Wiesława Dominika Wranik, Dorota Anna Zielińska, Liesl Gambold and Serperi Sevgur

Health Policy, 2019, vol. 123, issue 2, 191-202

Abstract: Health Technology Assessment is used to support the process of drug appraisal and reimbursement decisions in a variety of health systems. Examples can be found in mature Western countries, such as Canada, and in emerging economies of Central and Eastern Europe, such as Poland. The value of HTA in the process is influenced by the evidence used and the stakeholders involved.

Date: 2019
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0168851018303373
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:hepoli:v:123:y:2019:i:2:p:191-202

DOI: 10.1016/j.healthpol.2018.12.001

Access Statistics for this article

Health Policy is currently edited by Katrien Kesteloot, Mia Defever and Irina Cleemput

More articles in Health Policy from Elsevier
Bibliographic data for series maintained by Catherine Liu () and ().